iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies Anthony Japour, M.D., a seasonedbiotech and pharmaceutical executive with over 30 years of experience, appointed as Chief Executive Officer Camillo Ricordi, M.D., one of the world's leading scientists in diabetes cure-focused research, cell transplantation and regenerative medicine, appointed as Chief Scientist SAN MATEO, CA / ACCESSWIRE / June 9, 2021 / iTolerance, Inc . ("iTolera...
Source: finanznachrichten.de